Cargando…

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment

PURPOSE: Triple therapy versus dual therapy for chronic pulmonary obstructive disease (COPD) can reduce symptoms, limit the risk of acute exacerbations (AEs) as well as improve lung function. Currently, studies that feature clinically important deterioration (CID) as a composite endpoint to assess t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Wen-Chien, Wu, Biing-Ru, Liao, Wei-Chih, Chen, Chih-Yu, Chen, Wei-Chun, Hsia, Te-Chun, Tu, Chih-Yen, Chen, Chia-Hung, Hsu, Wu-Huei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764554/ https://www.ncbi.nlm.nih.gov/pubmed/33376318 http://dx.doi.org/10.2147/COPD.S279482

Ejemplares similares

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: Huang, Wei-Chun, et al.
Publicado: (2022)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis
por: Chen, Ching-Yi, et al.
Publicado: (2020)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
por: Tariq, Syed Mohammad, et al.
Publicado: (2017)

And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?
por: Beeh, Kai M.
Publicado: (2018)

Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
por: Plaza, Vicente, et al.
Publicado: (2023)

Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study
por: Lee, Ye Jin, et al.
Publicado: (2021)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework
por: Chen, Chun-Yu, et al.
Publicado: (2023)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2021)

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA
por: Vos, Wim, et al.
Publicado: (2016)

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
por: Rogliani, Paola, et al.
Publicado: (2022)

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
por: Spina, Domenico
Publicado: (2015)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2018)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

Is the Combination of ICS and LABA, a Therapeutic Option for COPD, Fading Away?
por: Oh, Yeon-Mok
Publicado: (2017)

Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
por: Andreas, Stefan
Publicado: (2020)

Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
por: Gong, Yiwen, et al.
Publicado: (2022)

Endobronchial Ultrasound Changed the World of Lung Cancer Patients: A 11-Year Institutional Experience
por: Chen, Chia-Hung, et al.
Publicado: (2015)

Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience
por: Chen, Chia-Hung, et al.
Publicado: (2017)

A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease
por: Huang, Wei-Chun, et al.
Publicado: (2021)

Predictors of ICS/LABA prescribing in COPD patients: a study from general practice
por: Drivenes, Elin, et al.
Publicado: (2014)

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018)

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
por: Han, MeiLan K., et al.
Publicado: (2018)

Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
por: Palli, Swetha R, et al.
Publicado: (2021)

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
por: Price, David B., et al.
Publicado: (2016)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ef3a35c7fsv7u4t2h3mr5pl897